All In Biotech

NDA 022527 · Novartis

Gilenya

Fingolimod Hydrochloride · Oral

NovelBreakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Sep 21, 2010

Approved uses

3

Original approval plus efficacy supplements

Registered trials

92

31 Phase 3, 4 recruiting

FAERS reports

81,755

40,666 serious, 1,120 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 22, 2026.

GILENYA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. GILENYA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )

Mechanism: Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • GILENYA · FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • GILENYA · FINGOLIMOD HYDROCHLORIDE EQ 0.25MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Fingolimod" as an intervention, any sponsor and status, largest first.

All 92 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue10,604
  • multiple sclerosis relapse7,266
  • headache7,128
  • dizziness5,278
  • white blood cell count decreased3,936
  • gait disturbance3,747
  • hypoaesthesia3,669
  • fall3,422
  • lymphocyte count decreased3,407
  • nausea3,362
  • malaise3,069
  • memory impairment2,942

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
201013
20112,683
20124,662
20134,226
20143,074
20158,196
201610,022
201710,260
201811,493
201911,029
20206,536
20213,850
20222,992
20231,440
2024670
2025411
2026197

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Gilenya (Fingolimod HCl)

2024 spending

$53.7M

Beneficiaries

839

4,535 claims

Per beneficiary

$63,964

$337.02 per unit

View as table
YearSpending
2020$449,518,264
2021$408,502,681
2022$363,110,730
2023$125,490,483
2024$53,665,922

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 236 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.